4-bromo-2-(4-methoxybenzyl)-1-methylbenzene | 333361-15-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-2-(4-methoxybenzyl)-1-methylbenzene
• 英文别名: 4-bromo-1-methyl-2-(4-methoxy-benzyl)-benzene；(5-bromo-2-methyl-phenyl)-(4-methoxy-phenyl)-methane；5-bromo-2-methyl-4'-methoxydiphenylmethane；4-bromo-2-[(4-methoxyphenyl)methyl]-1-methylbenzene
• CAS: 333361-15-2
• 化学式: C₁₅H₁₅BrO
• 分子量: 291.187
• InChiKey: KRBNGGIQTIMZEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-bromo-2-(4-methoxybenzyl)-1-methylbenzene 、 (2R,3S,4S)-2,3,4,6-tetrakis-benzyloxy-5-benzyloxymethyl-5-hydroxyhexanoic acid methoxy-methyl-amide 在 正丁基锂 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正己烷 、 乙醚 为溶剂， 反应 16.5h， 以61%的产率得到(4S,5S)-3,4,5-tris-benzyloxy-2-[3-(4-methoxybenzyl)-4-methylphenyl]-6,6-bis-(4-methoxybenzyloxymethyl)tetrahydropyran-2-ol
  参考文献：
  名称：

  [EN] DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES
  [FR] DÉRIVÉS DE DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL

  摘要：

  本文描述了化合物(I)的结构式及其用途，用于治疗由钠葡萄糖转运体抑制剂（特别是SGLT2抑制剂）介导的疾病、状况和/或紊乱。本文披露的化合物对于预防和治疗肥胖及其相关的共病症特别是II型（2型）糖尿病具有用处。

  公开号：

  WO2010023594A1

文献信息

• Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
  申请人：ECKHARDT Matthias

  公开号：US20070073046A1

  公开（公告）日：2007-03-29

  The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R 1 , R 2 and R 3 are defined according to claim 1 and to intermediates of said processes.

  本发明涉及制备一般式I化合物的过程，其中基团R1、R2和R3根据权利要求1定义，并涉及所述过程的中间体。
• Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
  申请人：Himmelsbach Frank

  公开号：US20070004648A1

  公开（公告）日：2007-01-04

  Glucopyranosyloxy-substituted benzyl-benzene derivatives of the general formula I where the groups groups R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 , X and R 7a , R 7b , R 7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

  根据权利要求1定义的通用公式I的葡萄糖吡喃氧基取代的苄基苯衍生物，包括基团R1、R2、R3a、R3b、R4、R5、R6、X以及R7a、R7b、R7c，包括互变异构体、立体异构体、它们的混合物以及它们的盐。根据发明的化合物适用于治疗代谢紊乱。
• Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
  申请人：FRICK Wendelin

  公开号：US20110059910A1

  公开（公告）日：2011-03-10

  The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of type I and type II diabetes.

  这项发明涉及取代芳香族氟糖苷衍生物，以及其生理兼容盐和生理功能衍生物。该发明还涉及降低血糖和治疗I型和II型糖尿病的方法。
• C-aryl glucoside SGLT2 inhibitors and method
  申请人：——

  公开号：US20030114390A1

  公开（公告）日：2003-06-19

  A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula 1 alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

  提供了一种用于治疗糖尿病及相关疾病的方法，使用化合物formula1的SGLT2抑制剂量，可以单独使用，也可以与一个或多个其他抗糖尿病药物或其他治疗药物组合使用。
• Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
  申请人：——

  公开号：US20030064935A1

  公开（公告）日：2003-04-03

  Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formula 1 wherein R 1 , R 2 and R 2a are independently hydrogen, OH, OR 5 , alkyl, —OCHF 2 , —OCF 3 , —SR 5a or halogen; R 3 and R 4 are independently hydrogen, OH, OR 5b , alkyl, cycloalkyl, CF 3 , —OCHF 2 , —OCF 3 , halogen, —CONR 6 R 6a , —CO 2 R 5c , —CO 2 H, —COR 6b , —CH(OH)R 6c , —CH(OR 5d )R 6d , —CN, —NHCOR 5e , —NHSO 2 R 5f , —NHSO 2 Aryl, —SR 5g , —SOR 5h , —SO 2 R 5i , or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO 2 , or R 3 and R 4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO 2 ; R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5g , R 5h and R 5i are independently alkyl; R 6 , R 6a , R 6b , R 6c and R 6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R 6 and R 6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO 2 . A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent.

  从天然氨基酸的(D)或(L)对映体和具有公式1的化合物的1:1或2:1混合物中获得结晶配合物，其中R1、R2和R2a独立地为氢、OH、OR5、烷基、—OCHF2、—OCF3、—SR5a或卤素；R3和R4独立地为氢、OH、OR5b、烷基、环烷基、CF3、—OCHF2、—OCF3、卤素、—CONR6R6a、—CO2R5c、—CO2H、—COR6b、—CH(OH)R6c、—CH(OR5d)R6d、—CN、—NHCOR5e、—NHSO2R5f、—NHSO2芳基、—SR5g、—SOR5h、—SO2R5i，或者一个含有1至4个N、O、S、SO和/或SO2杂原子的五、六或七元杂环；R5、R5a、R5b、R5c、R5d、R5e、R5f、R5g、R5h和R5i独立地为烷基；R6、R6a、R6b、R6c和R6d独立地为氢、烷基、芳基、烷基芳基或环烷基，或者R6和R6a与它们连接的氮一起形成一个含有1至4个N、O、S、SO和/或SO2杂原子的五、六或七元杂环。还提供了一种用于治疗糖尿病和相关疾病的方法，该方法使用上述配合物的SGLT2抑制剂量单独或与另一种抗糖尿病药物或其他治疗药物联合使用。